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It was the best of times, it was the worst of times…” Charles Dickens, A Tale of Two Cities.  
The past decade has been one of unprecedented discovery in psychiatry. Large-scale genomic studies 
have identified hundreds of molecular risk factors, and illuminated the genetic architectures of major 
psychiatric conditions. And yet, with this knowledge has come a realisation that these disorders are 
highly polygenic, and that there is widespread pleiotropy of the risk alleles involved. These findings 
confirm long-held suspicions that our diagnostic categories do not describe biologically distinct 
conditions, and pose fundamental challenges for the approaches to disease modelling that have 
helped understand simpler Mendelian disorders. So, while progress has been immense, when and 
how will the promised impacts on clinical care be delivered?   
A major justification for the pursuit of psychiatric genomics is that it offers a potentially unbiased route 
into understanding pathogenesis, and, as a consequence, the promise of new, rationally designed 
treatments. The challenges presented by polygenicity and pleiotropy are formidable, requiring us to 
relate myriad complex patterns of genomic variation in individuals, to complex patterns of clinical 
variation, and to interpret them in terms of altered function of the most complex organ in the body. 
Overcoming these challenges will require new analytic and experimental approaches, many examples 
of which are described eloquently in this issue.  Notwithstanding the difficulties, our view is that, given 
significant heritabilities together with the complexity and inaccessibility of the brain, such studies offer 
the surest foundations on which to build mechanistic research. However, we need to be clear that it 
will require a coordinated and well-funded effort that will play out over the next decade or more and 
that therapeutic advances may take even longer.    
A second major justification of genomics is its potential to provide diagnostic tests or biomarkers for 
use in research into aetiology and mechanism, and also in clinical settings as we move towards 
precision psychiatry. How will emerging genomic discoveries impact here? Genomic discoveries are 
already being applied in psychiatry, albeit more so by medical geneticists than psychiatrists. 
Identification of CNVs through Chromosomal Microarrays  
(CMA) is increasingly becoming part of routine clinical testing for childhood neurodevelopmental 
disorders (1), and it seems likely sequencing to detect rare coding variants (RCVs) will become part of 
the clinical tool-kit. There have also been calls for extending CMA testing to schizophrenia (2). These 
developments will require suitably trained psychiatrists working with genetic counselors and medical 
geneticists. The results of such tests may offer patients and families a degree of diagnostic 
explanation, point to the need for genetic counseling, and indicate increased risk for associated 
physical co-morbidities. However, they do not currently offer much in the way of predictive 
information about specific psychiatric or behavioral outcomes, which can be highly variable between 
carriers of the same risk allele, or information of direct therapeutic relevance. Given the rarity of the 
pathogenic mutations, informative research will require coordinated data sharing across many centers 
perhaps along lines developed for rare genetic disorders (3).   
Another area where genomics may be poised to impact on clinical practice is in risk prediction. Various 
methods have been developed to quantify risk from common alleles (4). In the case of psychiatric 
disorders, these are underpowered for general population screening, but power is increasing as data 
from larger GWAS become available (4). The predictive power of polygenic testing has more 
immediate potential in groups already at increased risk, but the value of prediction depends not only 
on accuracy, but also on the availability of effective interventions that can be targeted to the high-risk 
groups to either prevent or mitigate the emergence of disorder. Further research is now needed to 
evaluate both power and utility in different groups and clinical settings and to evaluate decision aids 
based on combining polygenic scores with other risk variables. Areas showing some promise include 
first-episode psychosis (5) and clinical high-risk syndrome (6).   
The long-term aim of medical genomics is to pave the way for precision medicine in which healthcare, 
including prevention, treatment and care pathways, can be tailored more effectively to the needs of 
individuals or groups. Recent advances in genomics are grounds for considerable optimism, but, if 
genomics is to play its anticipated role, there are three important limitations of current knowledge 
that will need to be overcome. The first is the lack of ancestral diversity in GWAS studies, the vast 
majority of which have been carried out in European ancestry samples. Significantly less heritable 
variation in liability is explained when risk profiles derived from equivalent powered GWAS are applied 
trans-ethnically, and therefore well-powered GWAS studies are required in diverse populations, as are 
methods to deal with mixed ancestry, if we are to avoid further exacerbation of current global health 
disparities (4).   
The second limitation is that polygenic risk scores (PRS) and similar metrics are dirty signals in the 
epidemiological sense. GWAS have usually been based on prevalent samples from clinical populations, 
while control populations are often unrepresentatively healthy, and otherwise enriched for traits and 
behaviors that are associated with inclusion in research. Thus, the current PRS may be biomarkers not 
just for liability but also for chronicity (including non-response to, or non-compliance with, treatment), 
progression, factors influencing illness-behavior, and confounders such as educational attainment and 
socio-economic status that influence access to care.  Genomic research using a range of different 
ascertainment approaches will be required to understand these issues, but the payoff might be great; 
whereas variants associated with disease occurrence may be useful in informing prevention, those 
involved in disease progression may be more suitable for the development of new treatments (7).   
The third limitation of current findings is that most of the samples used for psychiatric GWAS have not 
been clinically phenotyped even to a depth normally considered appropriate in psychiatric research 
and, when they have, inconsistent methods have been employed across sites. Moreover, the majority 
of samples have been assessed at a single time-point, yet there is huge variability in disease course 
and outcome within our current diagnoses. It is unclear to what extent this reflects diagnostic 
heterogeneity, pharmacogenetic factors, environmental exposures, or a host of other variables 
influencing individual differences impacting behavior but there is a need to establish this. This will 
require a major effort to collate and collect suitably powered, well-phenotyped samples, to coordinate 
phenotyping across sites and make the data available to other researchers. Current and emerging 
population studies and cohorts can play a role here but typically mental health data are scanty in such 
samples, and there is a substantial ascertainment bias against people with severe psychiatric disorders 
such as schizophrenia and childhood neurodevelopmental disorders. It is hard to see how the required 
datasets can be achieved economically without access to routinely collected clinical data, ideally at a 
population level. In this endeavor, advances in ‘Big Data’ approaches including access to electronic 
health records and digital phenotyping offer great potential.   
Pharmacogenomics in relation to treatment response or adverse effects is another area ripe for 
development in psychiatry. To date, most interest has been focused upon studies of candidate 
genes encoding known drug metabolizing enzymes and the HLA system in determining risk 
to adverse effects (8). Genomics offers the prospect of undertaking wider, unbiased, searches, 
but again the key issue will be access to sufficiently powered samples containing reliable and 
valid phenotype data. There are however promising signs of progress from genomics. For 
example, common genetic variants have large effects on the metabolism of clozapine and its 
metabolites, opening the way for clinical studies assessing the use of pharmacogenomics in 
the clinical management of patients with treatment-resistant schizophrenia (9). Moreover, a 
recent study (10) has demonstrated that the high rates of neutropenia seen in African ancestry 
individuals taking clozapine are due to the high frequency of Benign Ethnic Neutropenia 
(BEN), and that this can be diagnosed with a simple SNP test. Acceptability and cost efficiencystudies 
are still lacking, but in principle, such a test would allow a much higher 
proportion of individuals of African ancestry to access clozapine treatment, individuals who 
are currently denied such access due to undiagnosed BEN. 
 
In conclusion, genomics has made impressive progress in identifying genetic risk factors and 
in beginning to clarify genetic architectures of a range of psychiatric conditions. Work is also 
underway to relate the complex genetic signals to specific biological processes. These 
advances are been driven by the application of increasingly sophisticated genomic, functional 
genomic and epidemiological methods. However, it is our view that, if these are to yield 
mechanistic and clinical insights that will benefit patients and lead to a paradigm shift in 
psychiatric practice, they must be coupled with more sophisticated approaches to defining 
and measuring phenotypes. It is time to put more psychiatry into psychiatric genomics if we 
want to put genomics into psychiatric practice. 
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